摘要
OBJECTIVE: Biologic agents targeting IgE, IL-5/IL-5Rα, IL-4Rα, and TSLP have transformed severe asthma outcomes, yet it remains unresolved whether planned discontinuation is safe once sustained control is achieved. We therefore compared the risk of exacerbation after planned biologic discontinuation with that of continued therapy in patients with severe asthma. METHODS: MEDLINE, Embase, and Cochrane were searched from inception to June 2026, and reference lists were hand-searched. RCTs and observational cohort studies were eligible if they enrolled patients (≥12 years) with severe asthma who achieved sustained control on an approved biologic (≥12 months) before planned discontinuation or tapering. Non-response-driven discontinuation and studies with ≤10 participants were excluded. The primary outcome was uncontrolled asthma or exacerbation within 12 months. Secondary outcomes included symptom scores, lung function, biomarker rebound, and resumption rate of biologics. RESULTS: Twenty-three studies were included (3 RCTs [n=897], 2 non-randomized comparator cohorts [n=77], 17 single-arm cohorts, 1 mixed-biologic registry [n=118]). Two randomized withdrawal trials, XPORT (omalizumab; risk ratio [RR] 1.59; 95% CI, 1.11-2.27) and COMET (mepolizumab; RR 1.29; 95% CI, 1.03-1.61), yielded a pooled RR of 1.36 (95% CI, 1.13-1.65; I² = 0%; moderate certainty). An exploratory pool adding DESTINATION (tezepelumab; RR 1.22; 95% CI, 0.88-1.68; nonequivalent comparator) yielded RR 1.32 (95% CI, 1.13-1.56). No eligible dupilumab or reslizumab study was identified. Biomarker rebound followed class-specific kinetics. Baseline eosinophilia ≥300 cells/μL and exacerbation burden predicted relapse, with no withdrawal syndrome. CONCLUSION: Biologic discontinuation in severe asthma carries a moderate-certainty increased exacerbation risk. Because universal de-escalation criteria cannot yet be defined, decisions should be individualized, guided by eosinophil count, exacerbation history, remission duration, and biomarker trajectory, until prospective trial data become available. SYSTEMATIC REVIEW REGISTRATION: PROSPERO: CRD420261440934.